In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 700 ( 2023-06-14)
Kurzfassung:
Infection with hantaviruses can cause severe disease in humans, and virus-specific therapeutics and vaccines are urgently needed. Neutralizing antibodies represent a promising therapeutic option, but most antibodies fail to neutralize evolutionarily divergent hantaviruses, limiting their utility. To address this, Mittler et al. performed structural analysis on a recently identified broadly neutralizing antibody isolated from an individual who recovered from infection with an Old World hantavirus, Puumala virus. Using structural information and complementary binding, neutralization, and functional studies, the authors engineered an optimized variant of this patient-derived antibody that could protect against infection by Puumala virus and lethal challenge by Andes virus, a New World hantavirus, in rodent models. This broadly neutralizing antibody, ADI-65534, represents a potential therapeutic candidate to treat hantavirus infections. —Courtney Malo
Materialart:
Online-Ressource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.adg1855
Sprache:
Englisch
Verlag:
American Association for the Advancement of Science (AAAS)
Publikationsdatum:
2023